ReviewClinical kidney journal2023
The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy.
Review in Clinical kidney journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Efficacy and safety of sibeprenlimab in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.BMC nephrology · 2026Pooled it
- Efficacy and safety of BAFF/APRIL dual antagonists in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.BMC nephrology · 2025Pooled it
- From Susceptibility Loci to Therapeutic Targets: The Genetic Architecture of IgA Nephropathy.International journal of molecular sciences · 2026Review
- Structure and function of therapeutic antibodies approved by the US FDA in 2025.Antibody therapeutics · 2026Review
- Recent Advancements in the Therapeutic Landscape of IgA Nephropathy and the Impact of Dual Blockers: Telitacicept.Kidney medicine · 2026Review
- Zigakibart Potently Inhibits A Proliferation-Inducing Ligand-Mediated IgA Production, Addressing IgAN Pathogenesis Root Causes.Kidney international reports · 2026Article
- Reshaping the therapeutic landscape of IgA nephropathy: a Bayesian network meta-analysis on the comparative efficacy and safety of immunosuppressants and targeted agents.BMC nephrology · 2026Article
- Efficacy and safety of telitacicept in the treatment of pediatric IgA nephropathy: a retrospective study.Pediatric nephrology (Berlin, Germany) · 2026Observational
- Review
- Mechanistic Insights and Therapeutic Advances of Anti-Inflammatory Biologics in Immune-Mediated Glomerulonephritis: A Narrative Review.Journal of inflammation research · 2026Review
- Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial.Kidney international reports · 2025Article
- Targeting B cells in IgA nephropathy: from pathogenic insight to therapeutic horizon.Clinical kidney journal · 2025Article
- Review
- Exploring the molecular mechanism of budesonide enteric capsules in the treatment of IgA nephropathy based on bioinformatics.Scientific reports · 2025Article
- Telitacicept plus low-dose mycophenolate mofetil in the treatment of IgA nephropathy: a retrospective study.Clinical and experimental medicine · 2025Article
- Recent advances in pathogenetic concepts and disease modeling of IgA nephropathy.Clinical kidney journal · 2025Review
- Successful outcome of a refractory IgA vasculitis nephritis in children treated with telitacicept.CEN case reports · 2025Article
- Serum Cytokine Profile in IgA Nephropathy.Kidney medicine · 2025Article
- Engineering Dual Active Sites and Defect Structure in Nanozymes to Reprogram Jawbone Microenvironment for Osteoradionecrosis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Preliminary analysis of short-term real-world outcomes of telitacicept in high-risk IgA nephropathy.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in our understanding of the pathogenesis of immunoglobulin A nephropathy (IgAN) have led to the identification of novel therapeutic targets and potential disease-specific treatments. Specifically, a proliferation-inducing ligand (APRIL) has been implicated in the pathogenesis of IgAN, mediating B-cell dysregulation and overproduction of pathogenic galactose-deficient IgA1 (Gd-IgA1). Animal and clinical studies support the involvement of APRIL in the pathogenesis and progression of IgAN. An elevated level of APRIL is found in IgAN when compared with controls, which correlates with the level of Gd-IgA1 and associates with more severe disease presentation and worse outcomes. Conversely, anti-APRIL therapy reduces pathogenic Gd-IgA1 and IgA immune complex formation and ameliorates the severity of kidney inflammation and injury. Genome-wide association studies in IgAN have identified
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.